Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 265 de 371.

Grafa
Health

HUTCHMED swings to $457M net income on asset sale and global FRUZAQLA® growth

HUTCHMED (NASDAQ:HCM) reported a net income of $456.9 million for the full year 2025, a nearly 12-fold increase from the prior year, primarily driven by a one-time divestment gain and the continued global expansion of its oncology portfolio.

Leia mais: HUTCHMED swings to $457M net income on asset sale and global FRUZAQLA® growth
Grafa
Technology

WISeKey FY2025 revenue climbs 58% as quantum security pivot accelerates

WISeKey International Holding (NASDAQ:WKEY) reported a 58% increase in annual revenue and a significant expansion of its liquidity position for fiscal year 2025, driven by surging demand for secure semiconductors and the consolidation of key acquisitions.

Leia mais: WISeKey FY2025 revenue climbs 58% as quantum security pivot accelerates
Grafa
Transport and logistics

Performance Shipping annual profit hits $50 million following fleet expansion

Performance Shipping (NASDAQ:PSHG), a global specialist in tanker vessel ownership, announced on Wednesday that its full-year net income for 2025 reached $50 million, an increase from the $43.7 million reported in 2024.

Leia mais: Performance Shipping annual profit hits $50 million following fleet expansion
Grafa

TScan Therapeutics reports IND clearances for two TCR-T candidates

TScan Therapeutics (NASDAQ:TCRX), a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-engineered T cell therapies for the treatment of cancer, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update focused on progress across its allogeneic TCR-T platform.

Leia mais: TScan Therapeutics reports IND clearances for two TCR-T candidates
Grafa
Health

Ocugen reports Q4 net loss of $17.7M with FY loss reaching $67.8M

Ocugen (NASDAQ:OCGN), a Malvern, Pennsylvania-based clinical-stage biotechnology company developing modifier gene therapies for ophthalmic and other diseases, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, alongside a business update highlighting progress across its three lead modifier gene therapy programs.

Leia mais: Ocugen reports Q4 net loss of $17.7M with FY loss reaching $67.8M